|
|
| 35.24 Data as of Dec 12 |  +0.01 / +0.03%Today’s Change | 19.71 Today|||52-Week Range 42.96 | +58.45% Year-to-Date |
| Glaxo, Theravance Launch Relvar Ellipta in Japan Dec 09 / MotleyFool.com | Theravance (THRX) in Focus: Stock Adds 5.0% - Tale of the Tape Dec 09 / Zacks.com |
| Positive Data on Glaxo/Theravance Drug - Analyst Blog Dec 09 / Zacks.com | 3 Biopharmas Hoping for Good News From the FDA Dec 03 / MotleyFool.com |
| Previous close | 35.23 |
| Today’s open | 35.21 |
| Day’s range | -- - -- |
| Volume | 970,140 |
| Average volume (3 months) | 922,436 |
| Market cap | $3.9B |
| Dividend yield | -- |
| Earnings growth (last year) | +85.82% |
| Earnings growth (this year) | -694.17% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | +453.84% |
| P/E ratio | NM |
| Price/Sales | 14.89 |
| Price/Book | 22.36 |
| Today’s change | Today’s % change | |
|---|---|---|
| OPKOPKO Health Inc | -0.39 | -3.98% |
| TAROTaro Pharmaceutical ... | +0.40 | +0.41% |
| VPHMViroPharma Inc | +0.01 | +0.02% |
| UTHRUnited Therapeutics ... | +0.69 | +0.77% |
| Next reporting date | February 6, 2014 |
| EPS forecast (this quarter) | -$0.38 |
| Annual revenue (last year) | $135.8M |
| Annual profit (last year) | -$18.5M |
| Net profit margin | -13.66% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer Rick E. Winningham |
CFO, Senior VP & Head-Investor Relations Michael W. Aguiar |
Corporate headquarters South San Francisco, California |
.
